NJ Adopts ERT Solution for Suicide Monitoring in Students
ERT, a leading provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, today announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University
ERT, a provider of technology solutions and services that increase the reliability and efficiency of high-quality patient data collection, announced that its electronic Suicide Risk Assessment (SRA) system – AVERT® – will be implemented by Rutgers University Behavioral Health Care (UBHC) as part of the New Jersey Youth Suicide Prevention Project (NJYSPP). Beginning this semester, AVERT will be used to identify and routinely assess suicide risk among high school and college students in six targeted NJ counties (Bergen, Camden, Hudson, Passaic, Middlesex and Monmouth). Suicide is the second leading cause of death among 15 to 24 year olds in the United States (2012). Funded by a grant administered by the Substance Abuse and Mental Health Services Administration, the NJYSPP is a comprehensive approach to youth suicide prevention, which provides gatekeepers in the counties with best-practice and evidence-based trainings in suicide prevention, intervention, and postvention at no charge. By using the AVERT self-assessment system, the NJYSPP’s objective is to help school-based gatekeepers proactively identify at-risk students and more efficiently refer them to trained mental health professionals in their community. Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
